Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin

Immunobiology. 1992 Feb;184(2-3):230-9. doi: 10.1016/S0171-2985(11)80477-8.

Abstract

In 1924 Ramon described the inactivation of diphtheria toxin by formaldehyde treatment. This method allowed the introduction of mass vaccination against diphtheria and tetanus and opened the way to the inactivation of viruses by chemical treatment. In this review we describe the use of genetic manipulations for the inactivation of pertussis toxin. The toxin inactivated by this new method is an antigen superior to those obtained by chemical treatment and has been used to develop a new vaccine against whooping cough.

Publication types

  • Review

MeSH terms

  • Animals
  • Bordetella pertussis
  • Humans
  • Mice
  • Pertussis Toxin*
  • Pertussis Vaccine / adverse effects
  • Pertussis Vaccine / immunology*
  • Recombinant Proteins / immunology
  • Recombinant Proteins / therapeutic use
  • Virulence Factors, Bordetella / immunology*
  • Virulence Factors, Bordetella / therapeutic use
  • Whooping Cough / prevention & control

Substances

  • Pertussis Vaccine
  • Recombinant Proteins
  • Virulence Factors, Bordetella
  • Pertussis Toxin